ArticleMicrobial biotechnology2013
Saturation mutagenesis of selected residues of the α-peptide of the lantibiotic lacticin 3147 yields a derivative with enhanced antimicrobial activity.
Article in Microbial biotechnology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed.
- Phylogeny-guided genome mining of roseocin family lantibiotics to generate improved variants of roseocin.AMB Express · 2023Article
- Resistance to the Bacteriocin Lcn972 Deciphered by Genome Sequencing.Microorganisms · 2023Article
- Demystifying Bacteriocins of Human Microbiota by Genome Guided Prospects: An Impetus to Rekindle the Antimicrobial Research.Current protein & peptide science · 2022Review
- Substrate Sequence Controls Regioselectivity of Lanthionine Formation by ProcM.Journal of the American Chemical Society · 2021Article
- Accelerated antimicrobial discovery via deep generative models and molecular dynamics simulations.Nature biomedical engineering · 2021Article
- Multispecies activity screening of microcin J25 mutants yields antimicrobials with increased specificity toward pathogenic Salmonella species relative to human commensal Escherichia coli.Biotechnology and bioengineering · 2018Article
- The potency of the broad spectrum bacteriocin, bactofencin A, against staphylococci is highly dependent on primary structure, N-terminal charge and disulphide formation.Scientific reports · 2018Article
- In Vitro Biosynthesis and Substrate Tolerance of the Plantazolicin Family of Natural Products.ACS chemical biology · 2016Article
- Lanthipeptides: chemical synthesis versus in vivo biosynthesis as tools for pharmaceutical production.Microbial cell factories · 2016Review
- Bioengineering Lantibiotics for Therapeutic Success.Frontiers in microbiology · 2015Review
- Engineering unnatural variants of plantazolicin through codon reprogramming.ACS chemical biology · 2013Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The lantibiotic lacticin 3147 consists of two ribosomally synthesized and post-translationally modified antimicrobial peptides, Ltnα and Ltnβ, which act synergistically against a wide range of Gram-positive microorganisms. We performed saturation mutagenesis of specific residues of Ltnα to determine their functional importance. The results establish that Ltnα is more tolerant to change than previously suggested by alanine scanning mutagenesis. One substitution, LtnαH23S, was identified which improved the specific activity of lacticin 3147 against one pathogenic strain, Staphylococcus aureus NCDO1499. This represents the first occasion upon which the activity of a two peptide lantibiotic has been enhanced through bioengineering.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.